|Dr. Gail F. McIntyre||CEO & Director||453.34k||N/A||1963|
|Mr. Vinay Shah||Chief Financial Officer||463.51k||N/A||1962|
|Dr. Jeffrey L. Cleland||Co-Founder||N/A||N/A||1965|
|Dr. Joshua Silverman Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Randy L. Anderson||Sr. VP of Data Sciences||N/A||N/A||N/A|
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Aravive, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.